Actively Recruiting
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
Led by Guangzhou Lupeng Pharmaceutical Company LTD. · Updated on 2025-09-23
200
Participants Needed
3
Research Sites
312 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
CONDITIONS
Official Title
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) requiring treatment and have received 2 lines of standard care
- Diagnosed with relapsed or refractory non-Hodgkin's lymphoma associated with B-cell proliferation (such as CLL, SLL, MCL, MZL, WM) requiring treatment and have received 1 line of standard care
- Adequate blood cell function
- Adequate liver and kidney function
- Able to take study drug orally and willing to have medical examinations
- Men and women of reproductive potential willing to use effective birth control
You will not qualify if you...
- Diagnosed with Burkitt lymphoma, Burkitt-like lymphoma, lymphoblastic lymphoma/leukemia, or post-transplant lymphoproliferative disease
- History of other cancers within the past 3 years except successfully treated skin basal or squamous cell cancer, cervical carcinoma in situ, or breast cancer
- Received antitumor therapies, investigational treatments, major surgery, severe trauma, or radiotherapy within 4 weeks or 5 half-lives before first dose
- Received steroids, traditional herbal medicine for cancer, strong/moderate CYP3A inhibitors or inducers, or drugs causing QTc prolongation within 2 weeks before first dose
- Active infections including HIV, HBV, HCV, syphilis, bacterial or fungal infections
- Central nervous system disease with symptoms
- Autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura
- Severe gastrointestinal conditions affecting drug absorption
- Unable to tolerate urine collection, blood draws, lymph node biopsy, or bone marrow aspiration
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100089
Actively Recruiting
2
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
3
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
J
Jun Zhu, MD, PhD
CONTACT
Y
Yuqin Song, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here